Centiva Capital’s Nuvation Bio NUVB Stock Holding History

Centiva Capital’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,296	Closed	-$25.5K	–	1739
2022 Q4	$25.5K	Buy	+13,296	New	+$26.9K	﹤0.01%	1276

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Centiva Capital's NUVB Position: Q1 2023 in Review

Centiva Capital sold out of Nuvation Bio (NUVB) in Q1 2023, closing a stake of 13,296 shares — an estimated $25.5K sold.

Centiva Capital first reported a position in NUVB in Q4 2022 and held it in 1 quarter. The position peaked at $25.5K in Q4 2022. 129 funds tracked by Wall St. Rank hold NUVB as of Q1 2023.

Centiva Capital reported no remaining Nuvation Bio position as of Q1 2023 after selling out during the quarter.
Centiva Capital sold 13,296 Nuvation Bio shares in Q1 2023, an estimated $25.5K.
Centiva Capital first reported a position in Nuvation Bio in Q4 2022 and held it in 1 quarter.
Centiva Capital's Nuvation Bio position peaked at $25.5K in Q4 2022.
129 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2023.

Based on Centiva Capital's 13F filing for Q1 2023, filed 15 May 2023.